Skip to main content
AAO-HNSF 2024 Annual Meeting & OTO EXPO Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

EVP/CEO Spotlight Series

Laryngology/Broncho-Esophagology

Development, Safety, and Efficacy of PRGN-2012: A Therapeutic Vaccine for Recurrent Respiratory Papillomatosis

Saturday, September 28, 2024
9:30 AM – 10:30 AM EDT
Location: MBCC, 223
CME/MOC Credit: 1
Disclosure(s):
Clint T. Allen, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

PROGRAM DESCRIPTION: This presentation will highlight the pre-clinical development and phase 1/2 clinical study results of PRGN-2012, a gorilla adenovirus therapeutic vaccine immunotherapy designed to enhance HPV-specific immune responses in adult patients with recurrent respiratory papillomatosis. This vaccine has received Orphan Drug Designation from the United State Food and Drug Administration (FDA) and European Commission, and FDA Breakthrough Designation. Confirmed pivotal registration phase 2 clinical trial results are expected to be published at the time of this presentation.

Learning Objectives:

  1. Learn about the natural immune response to HPV types 6 or 11 in adult patients with RRP.
  2. Understand the potential for immunotherapy to be used to treat adult patients with RRP.
  3. Learn about differences in the papilloma microenvironment between patients that do and do not respond to HPV therapeutic vaccination.

    Lead Presenter(s)

  • Clint T. Allen, MD

    Tenured Investigator
    NIH
    Bethesda, MD, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.